Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Protox Therapeutics has entered into a collaborative research and clinical development agreement with BrainLAB for use of the Protox proprietary drug delivery software iPlan Flow in its planned pre-pivotal primary brain cancer clinical trial of PRX321.
Subscribe to our email newsletter
As part of the agreement, BrainLAB will supply and install its iPlan Flow software at all clinical sites participating in the pre-pivotal trial. The software will incorporate patient-specific information to monitor and potentially predict drug distribution in and around the brain tumor. Using the iPlan Flow software, neurosurgeons will be able to better plan treatments and optimize catheter placement for ideal delivery and distribution of PRX321.
In addition to the iPlan Flow software, BrainLAB will also provide hospital support services during this clinical study by installing computer hardware and software at the study sites, provide support and training for the participating neurosurgeons and perform data collection and analysis of study results.
Fahar Merchant, president and CEO of Protox, said: “We are very pleased to have secured this agreement with BrainLAB and see this as an important step in the commercial development of PRX321 for the treatment of primary and metastatic brain cancer. The use of this software should allow for patient-specific treatment resulting in optimal delivery and distribution of PRX321 which in turn could lead to more favorable outcomes in patients with this disease.”